PubMed Health⌕ Search

PubMed · 15654546

[Magnetic resonance imaging: technical aspects and recent developments].

Abstract

Magnetic resonance imaging (MR) is based on electromagnetic effects of rotating protons in hydrogen of water and organic materials. With a magnetic field and high frequency electromagnetic pulses, MRI generates data sets to be reconstructed as two-dimensional cross-sectional images or three-dimensional volumes of anatomic structures with excellent soft-tissue contrast. Since modern MR techniques have dramatically reduced acquisition times and motion artifacts, breathhold studies of moving organs such as the stomach and intestinum or heart and lung have become part of the daily routine. MRI does not apply ionizing radiation, therefore dynamic studies and repeated controls may be performed. Original contraindications such as metallic implants or electronic devices (pacemakers) have become relative in many cases. Since MR contrast media are considered not nephrotoxic when applied in regular dose, MRI provides a most valuable alter native for imaging studies and angiography in patients with renal insufficiency. The recent developments in the field of internal medicine include functional imaging of stomach, intestinum, heart and lung. Based on these experiences, protocols for whole-body MRI within reasonable acquisition time and at acceptable costs have been developed. In particular for screening and staging, such MRI proto cols might cover an even broader spectrum of applications in the near future. Based on the knowledge of recent trends and technical backgrounds, many perspectives are opened up for the further development of the method in interdisciplinary cooperation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jürgen Biederer. 2005-01-15. [Magnetic resonance imaging: technical aspects and recent developments].. https://doi.org/10.1007/s00063-005-1124-z

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A MAGIBU-based model for pediatric and juvenile CNS tumors: an in-house epigenetic decision-support framework compared with online DNA methylation classifiers.

Background: DNA methylation profiling is a tool that provides key support for central nervous system (CNS) tumor classification. However, diagnostically ambiguous pediatric cases may result in discordant outputs across classifiers. We developed MAGIBU, a cross-platform, projection-based framework that embeds individual methylomes into a fixed CNS reference landscape, ranking diagnostic entities by local epigenetic proximity to support clinician-led integrative diagnosis. Methods: As a proof-of-concept, we evaluated MAGIBU in eight morphologically challenging pediatric/juvenile CNS tumors with unresolved diagnoses after institutional and central pathology review. To establish a benchmark in the absence of a definitive histopathological ground truth, a consensus epigenetic reference was defined a priori for cases showing concordant results between the Heidelberg CNS Tumor Methylation Classifier and Methylscape Analysis. Comparisons were also performed with Epigenomic Digital Pathology (EpiDiP). To validate MAGIBU beyond this discovery cohort, performance was assessed at the family level across the CNS methylation spectrum (n = 678, 28 methylation families), on non-array platforms (whole-genome bisulfite sequencing and Oxford Nanopore), and in a focused analysis of the low-grade glioma and diffuse midline glioma compartment across four independent cohorts (n = 670). Results: In the discovery cohort, MAGIBU achieved high concordance with the consensus reference (Cohen's κ = 0.855), outperforming EpiDiP (κ = 0.278), which frequently placed low-grade tumors in proximity to higher-grade reference regions. Conclusions: MAGIBU provides a stable, quantitative differential diagnosis framework that mitigates the limitations of rigid categorical assignments. By leveraging a distance-based proximity metric, it offers a transparent decision-support tool that integrates effectively with clinical, radiological, and molecular data. While performance is inherently dependent on reference atlas composition, MAGIBU represents a robust complementary approach for the diagnostic workup of ambiguous CNS tumors.

Brain↗

1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans.

Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088 non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only) between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and somewhat larger in deletion carriers-the latter potentially mediated by ICV or cortical surface area. These results shed light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on specific brain structures and effect on cognitive function.

Brain↗